#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	11682	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2193	519.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1605	1605	C	698	C	613	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21954	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3668	586.8	0	.	n	.	0	T695C	SNP	695	695	T	1170	1170	C	797	C	711	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21954	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3668	586.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1812	1812	A	613	A	557	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21954	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3668	586.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2446	2446	C	687	C	604	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21954	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3668	586.8	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2520	2520	G	701	G,A	622,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21954	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3668	586.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3072	3072	C	742	C,T	629,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1002	folP	852	852	100.0	folP.l6.c30.ctg.1	1679	57.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1054	1056	AGC	93;93;92	A;G;C	80;80;79	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2582	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3547	70.5	1	SNP	p	S91F	0	.	.	271	273	TCC	731	733	TCC	93;92;92	T;C;C	83;81;82	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2582	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3547	70.5	1	SNP	p	D95G	0	.	.	283	285	GAC	743	745	GAC	100;99;97	G;A;C	92;91;89	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2582	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3547	70.5	1	SNP	p	D95N	0	.	.	283	285	GAC	743	745	GAC	100;99;97	G;A;C	92;91;89	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	764	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1269	58.3	1	SNP	p	G45D	1	.	.	133	135	GAC	445	447	GAC	115;116;116	G;A;C	104;104;104	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	480	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	849	54.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2334	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2892	77.9	1	SNP	p	D86N	0	.	.	256	258	GAC	569	571	GAC	96;96;95	G;A;C	94;93;93	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2334	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2892	77.9	1	SNP	p	S87I	0	.	.	259	261	AGT	572	574	AGT	95;97;97	A;G;T	92;95;95	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2334	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2892	77.9	1	SNP	p	S87W	0	.	.	259	261	AGT	572	574	AGT	95;97;97	A;G;T	92;95;95	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2334	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2892	77.9	1	SNP	p	S87R	0	.	.	259	261	AGT	572	574	AGT	95;97;97	A;G;T	92;95;95	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2334	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2892	77.9	1	SNP	p	S88P	0	.	.	262	264	TCC	575	577	TCC	96;97;95	T;C;C	94;95;93	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2098	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2979	67.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1780	1782	GGC	54;56;56	G;G;C	49;50;50	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1287	1289	GCA	143;145;144	G;C;A	125;126;125	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1290	1292	ATC	140;139;139	A;T;C	123;122;122	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1302	1304	GTG	140;137;133	G;T;G	123;120;117	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1302	1304	GTG	140;137;133	G;T;G	123;120;117	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1806	1808	ACC	70;70;69	A;C,T;C	65;65,1;65	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1860	1862	GCG	53;53;54	G;C;G	52;52;53	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1860	1862	GCG	53;53;54	G;C;G	52;52;53	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1983	1985	GGC	89;89;88	G;G;C	75;76;74	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1992	1994	GGC	71;71;70	G;G;C	60;60;59	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2512	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2289	105.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2010	2012	CCG	51;49;48	C;C;G	49;43;44	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3734	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3228	112.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1148	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1881	59.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	483	483	C	60	C	54	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	A26V	NONSYN	76	78	GCC	363	365	GTC	111;110;107	G;T;C	103;103;99	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	429	431	GGA	116;117;121	G;G;A	98;97;98	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	546	548	GCT	88;88;87	G;C;T	80;81;80	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	552	554	AGC	86;86;85	A;G;C	78;79;78	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	644	645	CG	69;65	C;G	64;61	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	647	649	CAG	65;65;65	C;A;G	61;61;61	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	651	653	AAA	70;78;80	A;A;A	63;67;68	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	A125T	NONSYN	373	375	GCT	660	662	ACT	88;91;88	A;C;T	78;81;78	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	N134S	NONSYN	400	402	AAT	687	689	AGT	79;80;86	A;G;T	71;72;75	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	E137K	NONSYN	409	411	GAA	696	698	AAA	82;81;81	A;A;A	76;75;75	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	714	716	GAA	87;89;89	G;A;A	78;80;79	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	738	740	GCA	102;101;101	G;C;A	93;92;92	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	846	848	CAA	183;184;185	C;A;A	151;152;153	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	N189S	NONSYN	565	567	AAC	852	854	AGC	181;181;181	A;G;C	150;149;149	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	M209I	NONSYN	625	627	ATG	912	914	ATC	155;155;155	A;T;C	128;127;127	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	0	.	p	.	0	E210fs	FSHIFT	628	628	G	915	915	G	154	G	127	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	1	SNP	p	G120K	1	.	.	358	360	AAG	644	646	CGG	69;65;65	C;G;G	64;61;61	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	1	SNP	p	A121D	1	.	.	361	363	GAC	647	650	CGC	65;65;71	C;G;C	61;61;63	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1318	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1610	80.2	1	SNP	p	D121N	0	.	.	361	363	GAC	647	650	CGC	65;65;71	C;G;C	61;61;63	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	4846	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4889	97.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1964	1966	AAT	119;121;123	A;A;T	106;106;108	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	376	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	966	37.5	1	SNP	p	V57M	1	.	.	169	171	ATG	498	500	ATG	60;60;63	A;T;G	50;50;53	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
